Important Safety Information Sermorelin is a prescription medication requiring evaluation by a licensed healthcare provider Compounded sermorelin is not FDA-reviewed for safety, quality, or efficacy Do not use if you have active cancer, diabetic retinopathy, or are pregnant or breastfeeding Report any unusual symptoms to your healthcare provider promptly Store and handle your medication according to pharmacy instructions Never share your medication with others This information is for educational purposes only and does not constitute medical advice
BPC-157 has been reported to upregulate VEGFR2 (vascular endothelial growth factor receptor 2) and activate the Akt-eNOS pathway, which raises nitric oxide production in blood-vessel walls (Hsieh et al., Journal of Molecular Medicine, 2017
(2025) Yuan et al
Tabla de protocolos Avanzado 750 mcg split AM/PM Vasubcut Momento de la inyeccin8 semanas activo / 4 semanas de descanso Principiante 250 mcg once daily Vasubcut Momento de la inyeccin4 semanas activo / 4 semanas de descanso Estndar 500 mcg split AM/PM Vasubcut Momento de la inyeccin6 semanas activo / 4 semanas de descanso Resumen de seguridad Contraindicaciones Cncer activo o historia reciente
In episode #158 of the popular Joe Rogan Experience podcast, Rogan advocated for the benefits of BPC-157, calling attention to its healing and recovery potential
PubMed Mihovilovic, K., Sever, M., Zoricic, I., et al